Financials in USD. Standardized financial statements.
A compact view of how Baijin Life Science Holdings Limited turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $135.56M | $53.68M | $86.88M | $62.65M | $43.32M | $111.98M | $171.27M | $187.36M | $212.23M | $210.02M |
| Revenue Growth? | +152.5% | -38.2% | +38.7% | +44.6% | -61.3% | -34.6% | -8.6% | -11.7% | +1.1% | 0.0% |
| Cost of Revenue? | $93.57M | $35.58M | $79.05M | $51.66M | $51.95M | $83.43M | $122.75M | $132.26M | $158.08M | $150.82M |
| Gross Profit? | $41.99M | $18.10M | $7.83M | $10.99M | -$8.62M | $28.55M | $48.52M | $55.09M | $54.15M | $59.20M |
| Gross Margin? | +31.0% | +33.7% | +9.0% | +17.5% | -19.9% | +25.5% | +28.3% | +29.4% | +25.5% | +28.2% |
| Operating Expenses? | $43.98M | $27.68M | -$1.71M | $21.34M | $34.06M | $70.31M | $82.32M | $78.77M | $77.45M | $78.30M |
| Operating Income? | -$2.00M | -$9.58M | $9.54M | -$11.09M | -$47.64M | -$272.22M | -$40.87M | -$128.78M | -$24.36M | -$10.56M |
| EBITDA? | $6.26M | -$6.32M | $11.18M | -$9.73M | -$45.45M | -$268.12M | -$38.51M | -$100.02M | -$21.84M | -$6.40M |
| Income Before Tax | -$1.36M | -$8.53M | $8.73M | -$15.46M | -$52.08M | -$280.40M | -$43.22M | -$128.56M | -$24.28M | -$10.86M |
| Income Tax Expense | -$1.28M | $16,000 | $0 | $0 | -$292,000 | $1.42M | -$404,000 | $1.23M | -$396,000 | $82,000 |
| Net Income? | -$316,000 | -$7.45M | $8.68M | -$15.46M | -$51.78M | -$281.82M | -$42.82M | -$129.79M | -$23.89M | -$10.94M |
| EPS? | $-0.00 | $-0.01 | $0.01 | $-0.04 | $-0.22 | $-1.48 | $-0.24 | $-0.73 | $-0.14 | $-0.08 |
| Diluted EPS? | $-0.00 | $-0.01 | $0.01 | $-0.04 | $-0.22 | $-1.48 | $-0.24 | $-0.73 | $-0.14 | $-0.08 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality